Concord Biotech gets USFDA EIR for Limbasi facility
Advertisement
Ahmedabad: Through a recent BSE filing, Concord Biotech Limited has notified that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) indicating closure of inspection and classifying the Limbasi (Unit III) facility as "no action indicated" ("NAI").
NAI means no objectionable conditions or practices were found during the inspection (or the objectionable conditions found do not justify further regulatory action).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.